INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Public company

TRDAEntrada Therapeutics, Inc.

CIK 0001689375

EDGAR filingsOpen in network
Disclosed transactions8
Buys / sells0 / 5
Max Insider Score24
Connections5with evidence

TRDA · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
24
PK
Parmar KushDirector
TRDAEntrada Therapeutics, Inc.
Open-market sale
SELL$73K
10.5K sh
Aug 6, 2026Aug 10, 2026
traded Aug 6, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Parmar KushDirector · Aug 10, 2026
  • ← Insider ofevidence
    Radhakrishnan MahaDirector · Jun 12, 2026
  • ← Insider ofevidence
    Sethuraman NatarajanPresident, Research & Develop. · May 4, 2026
23
PK
Parmar KushDirector
TRDAEntrada Therapeutics, Inc.
Open-market sale
SELL
$647K
92.4K sh
Aug 10, 2026
Aug 10, 2026
traded Aug 10, 2026
+0d
SEC FORM 4

Evidence

23
PK
Parmar KushDirector
TRDAEntrada Therapeutics, Inc.
Open-market sale
SELL$358K
52.3K sh
Aug 7, 2026Aug 10, 2026
traded Aug 7, 2026
+3dSEC FORM 4

Evidence

9
RM
Radhakrishnan MahaDirector
TRDAEntrada Therapeutics, Inc.
Grant or award
A—
19.0K sh
Jun 10, 2026Jun 12, 2026
traded Jun 10, 2026
+2dSEC FORM 4

Evidence

3
DJ
Dowden Nathan JPresident & COO
TRDAEntrada Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$26K
15.0K sh
May 4, 2026May 4, 2026
traded May 4, 2026
+0dSEC FORM 4

Evidence

17
DJ
Dowden Nathan JPresident & COO
TRDAEntrada Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$230K
15.0K sh
May 4, 2026May 4, 2026
traded May 4, 2026
+0dSEC FORM 4

Evidence

7
DJ
Dowden Nathan JPresident & COO
TRDAEntrada Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
15.0K sh
May 4, 2026May 4, 2026
traded May 4, 2026
+0dSEC FORM 4

Evidence

20
SN
Sethuraman NatarajanPresident, Research & Develop.
TRDAEntrada Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$399K
25.9K sh
May 4, 2026May 4, 2026
traded May 4, 2026
+0dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Dowden Nathan JPresident & COO · May 4, 2026